AXDX Accelerate Diagnostics, Inc.: שווי פעילות לרווח לפני ריבית, מסים ופחת

This daily price chart for Accelerate Diagnostics (AXDX) reflects an EV/EBITDA of , accounting for the strategy of leasing expensive equipment to expand its market presence. The business is based on accelerated antibiotic selection via the Accelerate Pheno system, saving lives in intensive care units. Demand for such tests remains stable and is not subject to economic fluctuations, depending solely on the update of government protocols.

This ratio compares the total enterprise value, including debt, to its operating profit before interest, taxes, depreciation, and amortization. For Accelerate Diagnostics (AXDX), which implements rapid sepsis tests, this metric assesses the efficiency of capitalizing on its technological breakthrough. By analyzing the EV/EBITDA ratio, an investor determines the extent of asset overvaluation relative to the actual cash flow generated from diagnostics.